Alphamab Oncology, a Chinese biopharma company that specializes in the development of innovative biologics for cancer therapy, announced on Tuesday that it has secured US$60 million in a series B round of financing led by New York-based asset management firm Hudson Bay Capital Management.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
